Your session is about to expire
← Back to Search
DMPA-SC for Birth Control
Study Summary
This trial compares self-administered contraception to provider-administered contraception and will look at continuation rates, pregnancy, side effects, satisfaction & associations between patient characteristics & continuation. It will help increase access to self-administered contraception & patient contraceptive autonomy.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: DMPA-SC
- Group 2: DMPA-IM
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the Food and Drug Administration given their seal of approval to DMPA-IM?
"There is a considerable amount of research supporting DMPA-IM's safety, which was enough for it to be awarded the maximum score on our scale: 3. This decision was based off of its current status as an approved Phase 4 medication."
Are there any unfilled positions available to participants in this experiment?
"Affirmative, the information on clinicaltrials.gov indicates that this study is actively seeking participants. It was inaugurated on August 1st 2022 and has recently been updated as of February 18th 2023. This trial requires 653 individuals across a single site to take part in it."
How many participants have enrolled in the study thus far?
"Affirmative. Clinicaltrials.gov's records show that this study began recruiting on August 1st 2022, and was last updated on February 18th 2023. 653 participants need to be enrolled at one clinical site for the trial to continue as planned."
Share this study with friends
Copy Link
Messenger